Literature DB >> 6982444

The role of cytotoxic T lymphocytes in the pathogenesis of Vogt-Koyanagi-Harada disease.

N Maezawa, A Yano, M Taniguchi, S Kojima.   

Abstract

Peripheral blood lymphocytes (PBL) were isolated from blood of 6 patients with Vogt-Koyanagi-Harada disease (VKH), and their cytotoxic activity was assayed using 51Cr release from the labelled cells; the cytotoxicity was expressed as percentage release in reference to the complete release using saponin. The PBLs from the patients showed a significant cytotoxic activity against P-36 human melanoma cells, and the specificity of the reaction was confirmed by the cold target inhibition test and also by the use of HeLa-S3 human cervical carcinoma cells and B-16 mouse melanoma cells, since no significant cytotoxicity was seen against these cells. The cytotoxic activity was greatly reduced by pretreatment of the PBLs with monoclonal antihuman Leu-1 antibody plus the rabbit complement. It was, therefore, thought that the cytotoxic activity against the melanoma cells is mainly due to T cells. In addition, the cytotoxic activity was specifically blocked by monoclonal antihuman Leu-2a antibody, the specificity of which is distributed on cytotoxic/suppressor T cell subset of normal human peripheral lymphocytes and normal human thymocytes. A possibility was discussed as regards the involvement of the cytotoxic T lymphocytes in the pathogenesis of VKH.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982444     DOI: 10.1159/000309240

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  11 in total

1.  Lymphocyte subsets and ocular inflammation: future prospects for immune deviation therapy?

Authors:  A Kijlstra
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

2.  The Vogt-Koyanagi-Harada syndrome: association with hypothyroidism and diabetes mellitus.

Authors:  N Jaggarao; D Voth; J Jacobsen
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

3.  High incidence of glucose intolerance in Vogt-Koyanagi-Harada disease.

Authors:  N Yawata; S Nakamura; M Kijima; N Ikai; M Kanai; M Sugita; S Ohno
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

4.  Headache and bilateral visual loss in a young hypothyroid Indian man.

Authors:  P Wiesli; W Bernauer; J Furrer
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

5.  The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.

Authors:  Un Chul Park; In Hwan Cho; Eun Kyung Lee; Hyeong Gon Yu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-05       Impact factor: 3.117

6.  Mucosal-associated invariant T cells have therapeutic potential against ocular autoimmunity.

Authors:  Satoshi Yamana; Kensuke Shibata; Eiichi Hasegawa; Mitsuru Arima; Shotaro Shimokawa; Nobuyo Yawata; Atsunobu Takeda; Sho Yamasaki; Koh-Hei Sonoda
Journal:  Mucosal Immunol       Date:  2021-11-13       Impact factor: 7.313

7.  HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia.

Authors:  Alia Iqniebi; Ameera Gaafar; Atia Sheereen; Abdullah Al-Suliman; Gamal Mohamed; Khaled Al-Hussein; Khalid F Tabbara
Journal:  Mol Vis       Date:  2009-09-12       Impact factor: 2.367

Review 8.  The diagnosis and management of uveitis.

Authors:  E Anglade; S M Whitcup
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

9.  The use of intravitreal ranibizumab for choroidal neovascularization associated with vogt-koyanagi-harada syndrome.

Authors:  A M Kolomeyer; M S Roy; D S Chu
Journal:  Case Rep Med       Date:  2011-08-03

10.  Identification of immune hub genes participating in the pathogenesis and progression of Vogt-Koyanagi-Harada disease.

Authors:  Yiqi Wang; Yahan Ju; Jiajing Wang; Na Sun; Zhimin Tang; Huiqin Gao; Ping Gu; Jing Ji
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.